9
Feb
2018
BMS Makes Case for TMB, Express Scripts Sees Drug Price Slowdown, & Theravance Pockets $100M
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.